Stock CMND CLEARMIND MEDICINE INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Clearmind Medicine Inc.

Equities

CMND

CA1850534027

Delayed Nasdaq
Other stock markets
 18:51:26 03/06/2024 BST 		5-day change 1st Jan Change
1.1 USD -2.65% Intraday chart for Clearmind Medicine Inc. -3.51% -60.85%
05-10 Clearmind Medicine Inc. Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product CI
05-07 Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product
Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product
Clearmind Medicine Inc. Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product
Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment
Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment
Clearmind Applies to Cease Being a Reporting Issuer in Canada
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
Clearmind Medicine CEO Issues Letter to Shareholders
Clearmind Medicine Inc. Announces International Patent Application for Preventing and Treating Depression
Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China
Clearmind Medicine Inc. Receives Divisional Patent Approval by the China National Intellectual Property Administration
Clearmind Medicine : Condensed Interim Consolidated Financial Statements - Form 6-K
Clearmind Medicine Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024
SciSparc Enters Collaboration for the Development of Innovative Psychedelic-Based Pharmaceuticals
Clearmind Medicine : Appoints Distinguished Addiction Experts Professor Wim van den Brink and Professor Gabriele Fischer to Its Scientific Advisory Board
Clearmind Medicine : to Host ‘Psychedelics for Alcoholism‘ Virtual Educational Event on October 20
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CMND Stock
  4. News Clearmind Medicine Inc.
  5. Other languages
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW